不同化疗方案治疗晚期非小细胞肺癌成本-效果分析  

Different Chemotherapy Regimens for Advanced Non-small Cell Lung Cancer: Cost-Effect Analysis

作　　者：王宇[1] 盛明宇[1] 汤致强[1] 

机构地区：[1]中国医学科学院肿瘤医院药剂科,北京市100021

出　　处：《中国医院用药评价与分析》2007年第1期52-54,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:从药物经济学角度,观察比较TC(TAX+CBP)、GP(GEM+DDP)和NP(NVB+DDP)联合化疗方案的合理性。方法:50例晚期肺癌患者应用3种不同化疗方案治疗,TC组18例,NP组16例,GP组16例。结果:TC组有效率44.4%、NP组有效率37.5%、GP组有效率50.0%,3组之间的近期疗效无显著差异。主要毒性为骨髓抑制和胃肠道反应。C/E分别为410.33、362.63、313.05。结论:GP组治疗晚期非小细胞肺癌成本效果比较好,毒性反应可耐受,是目前治疗NSCLC的首选方案之一。OBJECTIVE：To observe and compare the rationality among three combined chemotherapy regimens - TC （TAX＋ CBP）,GP（GEM ＋ DDPi and NP （NVB ＋ DDP） from the perspective of pharmacoeconomics. METHODS： Fifty patients were enrolled in this study, 18 were assigned to TC group, 16 NP group and another 16 GP group. RESULTS： The effective rates of TC, NP and GP groups were 44.4 %, 37.5 % and 50.0 %, respectively, and the short - term therapeutic efficacies among three groups showed no statistical difference. The major toxicities wrere bone marrow suppression and gastrointestinal tract reactions. The cost - effectWeness ratios were 410.33, 362.63 and 313.05, respectively. CONCLUSION： GP is more satisfactory in curative efficacy and tolerable in its toxicity, and it is currently one of the first choices for the treatment of NSCLC.

关 键 词：非小细胞肺癌 化学治疗 成本-效果分析 

分 类 号：R979.1[医药卫生—药品]